Skip to main content

Advertisement

Table 1 Baseline patients’ characteristics by BMI category

From: The impact of baseline body mass index on clinical outcomes in metastatic breast cancer: a prospective study

Characteristic Total (n = 82) BMI (kg/m2) P value
<25 (n = 21) 25–29.9 (n = 34) ≥ 30 (n = 27)
Age (years)
Median (range) 47.5 (24–74) 41 (24–71) 46 (28–74) 50 (36–68) 0.014
ECOG-PS scale n%
0 8 (9.76) 2 (9.52) 2 (5.88) 4 (14.81) 0.108
1 60 (73.17) 13 (61.90) 30 (88.23) 17 (62.96)
2 14 (17.07) 6 (28.57) 2 (5.88) 6 (22.22)
No. of metastatic
1 site 40 (48.78) 8 (38.09) 15 (44.11) 17 (62.96) 0.180
≥ 2 sites 42 (51.22) 13 (61.90) 19 (55.88) 10 (37.04)
HER2
HER2+ 56 (68.29) 10 (47.62) 25 (73.52) 21 (77.77) 0.064
HER2− 22 (26.82) 10 (47.62) 6 (17.64) 6 (22.22)
Unknown 4 (4.88) 1 (4.76) 3 (8.82) 0 (0)
Hormone receptors
ER+PR+ 27 (32.92) 8 (38.09) 13 (38.23) 6 (22.22) 0.613
ER−PR− 39 (47.56) 8 (38.09) 14 (41.17) 17 (62.96)
ER+PR− 6 (7.31) 2 (9.52) 2 (5.88) 2 (7.41)
ER−PR+ 6 (7.31) 2 (9.52) 2 (5.88) 2 (7.41)
Unknown 4 (4.88) 1 (4.76) 3 (8.82) 0 (0)
Chemotherapy lines
1st line 37 (45.12) 11 (52.38) 15 (44.11) 11 (40.74) 0.836
2nd line 36 (43.90) 7 (33.33) 16 (47.05) 13 (48.14)
≥ 3rd line 9 (10.98) 3 (14.28) 3 (8.82) 3 (11.11)
Other medications
Statins 41 (50) 10 (47.62) 15 (44.11) 16 (59.26)  
Metastatic sites (n = 129) sites (n = 35) (n = 55) (n = 39)  
Bone 39 (30.23) 12 (34.29) 16 (29.09) 11 (28.21) 0.169
Visceral 61 (47.29) 18 (51.43) 29 (52.73) 14 (35.90)
Soft tissues 29 (22.48) 5 (14.29) 10 (18.18) 14 (35.90)